A blood test can show a rise in NAD⁺ metabolites within hours of taking a precursor. That is a meaningful biological finding, but it is not the same as proving a noticeable change in energy, training capacity or healthy ageing. The most useful NAD⁺ supplementation research examples separate these questions clearly: does an intervention raise NAD⁺ availability, does that influence a relevant cellular pathway, and do measurable human outcomes follow?
NAD⁺ is a coenzyme used throughout the body. It helps transfer energy from nutrients through oxidative phosphorylation, supports redox balance and acts as a substrate for enzymes involved in cellular stress responses, including sirtuins and PARPs. NAD⁺ availability can change with age, lifestyle, metabolic demand and tissue type. This has made NAD⁺ precursors – especially nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) – a focused area of human research.
The evidence is promising in places, early in others, and highly dependent on the population studied. That is not a weakness to overlook. It is exactly how responsible science progresses.
NAD⁺ supplementation research examples in humans
Human trials generally examine three connected but distinct outcomes: whether a precursor is absorbed and changes NAD⁺-related biomarkers; whether it affects a defined physiological measure; and whether it is well tolerated over the study period. A positive result in one category should not automatically be read as proof of every possible benefit.
Nicotinamide riboside can raise circulating NAD⁺ markers
A foundational study by Trammell and colleagues, published in Nature Communications in 2016, tested single oral doses of NR in healthy adults. Researchers observed dose-dependent increases in the blood NAD⁺ metabolome, including NAD⁺ itself and related compounds.
This matters because it answers a basic but essential question: can orally consumed NR enter the body’s NAD⁺ metabolic network? In this study, the answer was yes. However, the trial was designed around pharmacokinetics and biomarkers, not long-term performance, body composition or clinical outcomes. It demonstrates biological availability, not a universal wellness result.
A later randomised trial by Martens and colleagues, published in Nature Communications in 2018, studied 24 healthy adults aged 55 to 79 years who received NR or placebo for six weeks, followed by a crossover period. NR increased NAD⁺ levels in peripheral blood cells and was generally well tolerated. The researchers also explored measures related to cardiovascular function, but the small sample and exploratory design mean those findings need careful interpretation rather than broad conclusions.
Together, these studies provide a strong rationale for viewing NR as an NAD⁺ precursor in humans. They do not establish that every person will feel a change, nor do they show that higher blood NAD⁺ automatically means higher NAD⁺ in every tissue.
NR and metabolic outcomes: useful results can be neutral too
Not every well-conducted study finds an improvement in a functional outcome. That is valuable information, especially for people making considered choices about supplements.
In a 2018 trial published in The American Journal of Clinical Nutrition, Dollerup and colleagues gave 2 g of NR daily or placebo to men with obesity for 12 weeks. NR increased whole-blood NAD⁺, confirming target engagement, but it did not improve insulin sensitivity or several other metabolic measures assessed in the study.
This is an instructive example. Raising NAD⁺ status is a measurable biochemical effect. Whether that translates into a particular outcome may depend on baseline health, the tissue being examined, the dose, the intervention length and whether the pathway was meaningfully constrained in the first place. A person with a different age, activity level or metabolic profile may not respond in the same way, but neither should neutral findings be brushed aside.
NMN and muscle insulin sensitivity in a defined group
NMN has also moved into human research. A small randomised trial by Yoshino and colleagues, published in Science in 2021, investigated 250 mg of NMN daily for 10 weeks in postmenopausal women with prediabetes and overweight or obesity.
The researchers reported improved muscle insulin sensitivity in the NMN group, alongside changes in muscle gene expression associated with remodelling. This is an encouraging signal because the study used a clear physiological endpoint and a placebo-controlled design. Yet its relevance is necessarily specific: the participants had a particular metabolic profile, the group was small, and the intervention lasted 10 weeks.
It would be inaccurate to extend these findings directly to all healthy adults, athletes or people seeking support for day-to-day energy. It does, however, show why NAD⁺ biology deserves continued study in carefully selected human populations.
NMN, exercise and physical capability
Exercise-focused research is especially relevant to active adults, but it also requires restraint. In a 2021 study in GeroScience, Hu and colleagues examined NMN supplementation alongside structured exercise training in middle-aged and older adults. The trial reported improvements in some measures of aerobic capacity at higher NMN doses when combined with training.
The key phrase is “when combined with training”. The study does not suggest that a precursor replaces progressive exercise, adequate recovery, protein intake or sleep. It raises a more interesting question: could NAD⁺ support influence adaptation to a meaningful training stimulus in some contexts?
Further trials should test this question across different training statuses, sex, age groups and durations. For readers who train regularly, the sensible interpretation is not to expect a shortcut. It is to recognise that cellular energy metabolism may be one part of a much broader performance foundation.
How to assess NAD⁺ supplementation studies
A headline can make an early human trial sound more decisive than it is. Look first at who was studied. A result in older adults with a specific metabolic characteristic may be highly relevant to that group but less informative for a healthy 35-year-old endurance runner.
Next, look at the intervention itself. NR and NMN are different precursors, and dose, formulation, study length and adherence all matter. A trial lasting a few weeks can offer useful safety and biomarker data, while remaining too short to answer questions about sustained functional change.
Finally, distinguish biomarkers from outcomes people can experience or measure. Whole-blood NAD⁺, related metabolites and gene-expression changes are important because they show that a pathway may be responding. Outcomes such as exercise tests, muscle insulin sensitivity or validated physical-function measures answer a different question. The most informative research connects both.
What the evidence supports today
The current human literature supports a measured, science-led position. NR and NMN can increase NAD⁺-related biomarkers in several human studies. Early trials have also identified specific physiological signals worth investigating further, including in muscle metabolism and exercise contexts. At the same time, results are not uniform, longer-term data remain limited, and meaningful outcomes vary by study design and participant group.
For a proactive approach to cellular health, supplementation should sit alongside the fundamentals that continually shape NAD⁺ demand and resilience: regular exercise, sufficient sleep, a nutrient-dense diet, sensible alcohol intake and recovery that matches your workload. These are not glamorous additions to NAD⁺ biology. They are the conditions in which cellular energy systems are asked to perform.
Choose evidence with the same care you bring to your training, work and long-term health. NAD⁺ research is moving forward because researchers are asking increasingly precise questions – and that precision is the most valuable result to carry with you.
NAD⁺ Supplementation Research Examples: What They Show
A blood test can show a rise in NAD⁺ metabolites within hours of taking a precursor. That is a meaningful biological finding, but it is not the same as proving a noticeable change in energy, training capacity or healthy ageing. The most useful NAD⁺ supplementation research examples separate these questions clearly: does an intervention raise NAD⁺ availability, does that influence a relevant cellular pathway, and do measurable human outcomes follow?
NAD⁺ is a coenzyme used throughout the body. It helps transfer energy from nutrients through oxidative phosphorylation, supports redox balance and acts as a substrate for enzymes involved in cellular stress responses, including sirtuins and PARPs. NAD⁺ availability can change with age, lifestyle, metabolic demand and tissue type. This has made NAD⁺ precursors – especially nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) – a focused area of human research.
The evidence is promising in places, early in others, and highly dependent on the population studied. That is not a weakness to overlook. It is exactly how responsible science progresses.
NAD⁺ supplementation research examples in humans
Human trials generally examine three connected but distinct outcomes: whether a precursor is absorbed and changes NAD⁺-related biomarkers; whether it affects a defined physiological measure; and whether it is well tolerated over the study period. A positive result in one category should not automatically be read as proof of every possible benefit.
Nicotinamide riboside can raise circulating NAD⁺ markers
A foundational study by Trammell and colleagues, published in Nature Communications in 2016, tested single oral doses of NR in healthy adults. Researchers observed dose-dependent increases in the blood NAD⁺ metabolome, including NAD⁺ itself and related compounds.
This matters because it answers a basic but essential question: can orally consumed NR enter the body’s NAD⁺ metabolic network? In this study, the answer was yes. However, the trial was designed around pharmacokinetics and biomarkers, not long-term performance, body composition or clinical outcomes. It demonstrates biological availability, not a universal wellness result.
A later randomised trial by Martens and colleagues, published in Nature Communications in 2018, studied 24 healthy adults aged 55 to 79 years who received NR or placebo for six weeks, followed by a crossover period. NR increased NAD⁺ levels in peripheral blood cells and was generally well tolerated. The researchers also explored measures related to cardiovascular function, but the small sample and exploratory design mean those findings need careful interpretation rather than broad conclusions.
Together, these studies provide a strong rationale for viewing NR as an NAD⁺ precursor in humans. They do not establish that every person will feel a change, nor do they show that higher blood NAD⁺ automatically means higher NAD⁺ in every tissue.
NR and metabolic outcomes: useful results can be neutral too
Not every well-conducted study finds an improvement in a functional outcome. That is valuable information, especially for people making considered choices about supplements.
In a 2018 trial published in The American Journal of Clinical Nutrition, Dollerup and colleagues gave 2 g of NR daily or placebo to men with obesity for 12 weeks. NR increased whole-blood NAD⁺, confirming target engagement, but it did not improve insulin sensitivity or several other metabolic measures assessed in the study.
This is an instructive example. Raising NAD⁺ status is a measurable biochemical effect. Whether that translates into a particular outcome may depend on baseline health, the tissue being examined, the dose, the intervention length and whether the pathway was meaningfully constrained in the first place. A person with a different age, activity level or metabolic profile may not respond in the same way, but neither should neutral findings be brushed aside.
NMN and muscle insulin sensitivity in a defined group
NMN has also moved into human research. A small randomised trial by Yoshino and colleagues, published in Science in 2021, investigated 250 mg of NMN daily for 10 weeks in postmenopausal women with prediabetes and overweight or obesity.
The researchers reported improved muscle insulin sensitivity in the NMN group, alongside changes in muscle gene expression associated with remodelling. This is an encouraging signal because the study used a clear physiological endpoint and a placebo-controlled design. Yet its relevance is necessarily specific: the participants had a particular metabolic profile, the group was small, and the intervention lasted 10 weeks.
It would be inaccurate to extend these findings directly to all healthy adults, athletes or people seeking support for day-to-day energy. It does, however, show why NAD⁺ biology deserves continued study in carefully selected human populations.
NMN, exercise and physical capability
Exercise-focused research is especially relevant to active adults, but it also requires restraint. In a 2021 study in GeroScience, Hu and colleagues examined NMN supplementation alongside structured exercise training in middle-aged and older adults. The trial reported improvements in some measures of aerobic capacity at higher NMN doses when combined with training.
The key phrase is “when combined with training”. The study does not suggest that a precursor replaces progressive exercise, adequate recovery, protein intake or sleep. It raises a more interesting question: could NAD⁺ support influence adaptation to a meaningful training stimulus in some contexts?
Further trials should test this question across different training statuses, sex, age groups and durations. For readers who train regularly, the sensible interpretation is not to expect a shortcut. It is to recognise that cellular energy metabolism may be one part of a much broader performance foundation.
How to assess NAD⁺ supplementation studies
A headline can make an early human trial sound more decisive than it is. Look first at who was studied. A result in older adults with a specific metabolic characteristic may be highly relevant to that group but less informative for a healthy 35-year-old endurance runner.
Next, look at the intervention itself. NR and NMN are different precursors, and dose, formulation, study length and adherence all matter. A trial lasting a few weeks can offer useful safety and biomarker data, while remaining too short to answer questions about sustained functional change.
Finally, distinguish biomarkers from outcomes people can experience or measure. Whole-blood NAD⁺, related metabolites and gene-expression changes are important because they show that a pathway may be responding. Outcomes such as exercise tests, muscle insulin sensitivity or validated physical-function measures answer a different question. The most informative research connects both.
What the evidence supports today
The current human literature supports a measured, science-led position. NR and NMN can increase NAD⁺-related biomarkers in several human studies. Early trials have also identified specific physiological signals worth investigating further, including in muscle metabolism and exercise contexts. At the same time, results are not uniform, longer-term data remain limited, and meaningful outcomes vary by study design and participant group.
For a proactive approach to cellular health, supplementation should sit alongside the fundamentals that continually shape NAD⁺ demand and resilience: regular exercise, sufficient sleep, a nutrient-dense diet, sensible alcohol intake and recovery that matches your workload. These are not glamorous additions to NAD⁺ biology. They are the conditions in which cellular energy systems are asked to perform.
Choose evidence with the same care you bring to your training, work and long-term health. NAD⁺ research is moving forward because researchers are asking increasingly precise questions – and that precision is the most valuable result to carry with you.